Rallybio Corp
A clinical-stage biotech company developing therapies for severe and rare diseases.
RLYB | US
Overview
Corporate Details
- ISIN(s):
- US75120L1008
- LEI:
- Country:
- United States of America
- Address:
- 234 CHURCH STREET, 6510 NEW HAVEN
- Website:
- https://rallybio.com/
Description
Rallybio Corp. is a clinical-stage biotechnology company that develops and commercializes therapies for patients with severe and rare diseases. The company's development pipeline focuses on complement dysregulation and hematology. Key programs include RLYB116, a C5 inhibitor being investigated for complement-mediated diseases, and a therapy for the prevention of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT). Rallybio operates with a portfolio-based model, identifying and accelerating the development of assets such as small molecules and engineered proteins to address significant unmet medical needs.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Rallybio Corp filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Rallybio Corp
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Rallybio Corp via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
